KRAS and non-small cell lung carcinoma: Numerous researches found the co-mutation of KRAS and STK11/LKB1 in NSCLC patients receiving immunotherapy has been confirmed to be related to poor therapeutic effect (Di Federico et al. 2021; Skoulidis et al. 2018).